pyronaridine-artesunate (Pyramax)
GPTKB entity
Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
antiviral drug
|
| gptkbp:activeIngredient |
gptkb:artesunate
pyronaridine |
| gptkbp:approvedBy |
gptkb:World_Health_Organization
gptkb:European_Medicines_Agency |
| gptkbp:ATCCode |
gptkb:P01BF05
|
| gptkbp:brand |
Pyramax
|
| gptkbp:developer |
Shin Poong Pharmaceutical
|
| gptkbp:effect |
gptkb:Plasmodium_vivax
gptkb:Plasmodium_falciparum |
| gptkbp:form |
gptkb:tablet
fixed-dose combination granules for oral suspension |
| https://www.w3.org/2000/01/rdf-schema#label |
pyronaridine-artesunate (Pyramax)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
vomiting headache elevated liver enzymes |
| gptkbp:usedFor |
treatment of malaria
|
| gptkbp:WHOModelListOfEssentialMedicines |
included
|
| gptkbp:bfsParent |
gptkb:Medicines_for_Malaria_Venture
|
| gptkbp:bfsLayer |
7
|